[Symptomatic treatment versus combination chemotherapy in advanced non-small cell lung cancer].
To evaluate the effects on survival of combination chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Seventy patients with advanced NSCLC were pairingly divided into two equal groups: 35 patients who refused chemotherapy received symptomatic treatment; the other 35 patients received combined chemotherapy with mitomycin(8-10 mg/m2, dl), vindesine (3 mg/m2, dl, 8) cisplatin (20 mg/m2, dl-5), repeated every four weeks for 2-4 cycles and followed by oral administration of Ftorafur (FT-207) 200-300 mg tid, until recurrence or progression of disease. The overall median survival time in the chemotherapy group was 9 months, and 4.5 months in the symptomatically treated group. The one-year survival rate was 34.3% and 8.0% respectively. The major toxic effects of chemotherapy were gastrointestinal tract reactions and myelosuppression. Combination chemotherapy can prolong survival time in patients with advanced NSCLC.